Streamlined DXA Image Analysis for Clinical Trials

End-to-End Support of Studies involving DXA:

Osteoporosis, Oncology, Infection disease, Nutrition and Metabolism Studies and more

Streamlined DXA Analysis for Clinical Trials

Did you miss our live discussion?

Watch this webinar here.


Shorten Time to Market: Every day in drug development counts as patients are waiting for new treatments. IAG’s streamlined processes and global network expedite clinical trials without compromising quality.

Expertise You Can Trust: IAG has a proven track record of tackling complex imaging challenges – from managing sites, resolving queries, integrating novel endpoints and supporting overall stakeholder collaboration.

Global Support, Local Focus: We placed our team of imaging specialists in geographically important hubs (EU, Asia, USA), which enables them to provide efficient answers to the sites and support global trials, with speed.

Value-Driven Partnerships: We prioritize delivering the highest quality data at competitive cost. We thrive to build long term relationships with our partners and clients.


IAG’s team experience with using DXA and X-ray in clinical trials spans over 40 years, with the company supporting large registrational studies and research PoC projects, since 2016. We understand the value of time and transparency in clinical development, and power our trials with DYNAMIKA platform. It is designed to efficiently process imaging data, support all trial stakeholders, deliver results via reports or dashboards. Thus, helping our partners, readers and sponsors to fast decisions.

Read our case studies: from saving significant budgets: ‘35% Trial Budget Reduction’ to ‘Reducing Length & Cost of Trials through Patient Stratification‘.

Case Study: One specific study, involving DXA analysis makes a vivid example. In 2021, IAG was contacted by a large European biotech company to support their Phase III trial. The objective was to utilize X-ray and DXA scans for combined eligibility as one of the criteria for the inclusion / exclusion of patients in their protocol. The Sponsor was looking for experts in the field, who can bring global network of sites, and execute screening with speed. IAG’s team partnered with the CRO and together we embarked on accelerating recruitment. The Study recruited faster than exepcted, saving Sponsor significant time and money. The data is currently being finalized to be submitted for regulatory review.

+1200 patients

+50 Sites in all Europe

0.4 day from the upload to the QC report

2.2 days from QC report to Final Report

hosted all the DXA and X-ray images and analysis


Reproducibility: Properly acquired and correctly analysed DXA scans result in very low precision errors, allowing the detection of subtle changes over time.

Validity: Evaluating and monitoring instrument calibration throughout your study is vital for validating patient BMD results. IAG ensures that Instrument Quality Control (IQC) data are collected correctly and available for analysis to support patient results.

Accessibility: IAG has collaborated with numerous imaging facilities and can recommend high-performing DXA sites for your study, reducing risk and improving patient recruitment.

Transparency: DYNAMIKA is a proprietary, secure image transfer and processing system that provides real-time access to tracking information throughout the study.

Would you be interested in receiving regular updates and
staying informed with the latest news?
We invite you to subscribe to our newsletter.


Managing data across multiple sites in clinical trials can be complex and time-consuming. Recognizing this challenge, our team of experts developed DYNAMIKA. It is IAG’s proprietary enterprise-scale cloud-based platform for imaging processing and data management. It works across multi-centre trial settings to enable central imaging review.​ This one comprehensive software system controls trial progress, conducts central reads and, when needed, it can be integrated with AI tools for earlier read-outs and decision support. Read more here.


Image Analysis Group is a unique partner to life sciences companies. Our goal is to accelerate novel drug developments, by using the right analytical tools and a modern trial infrastructure. At IAG, we are committed to helping our biotech and pharma partners to efficiently develop novel life-changing medicines, accelerating their R&D pipelines through advanced analytics, IAG’s technology solutions and imaging contract research services. We see each project as an oportunity to build a long lasting partnership and to become an extension of your team.

If you have any inquiries or require assistance,
please do not hesitate to reach out to us!